Cargando…

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

BACKGROUND: No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for IDS and the prognosis-associated fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Xia, Deng, Fei, Lv, Mengmeng, Ren, Binhui, Guo, Wenwen, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134071/
https://www.ncbi.nlm.nih.gov/pubmed/27912779
http://dx.doi.org/10.1186/s13048-016-0294-z
_version_ 1782471395852156928
author Xu, Xia
Deng, Fei
Lv, Mengmeng
Ren, Binhui
Guo, Wenwen
Chen, Xiaoxiang
author_facet Xu, Xia
Deng, Fei
Lv, Mengmeng
Ren, Binhui
Guo, Wenwen
Chen, Xiaoxiang
author_sort Xu, Xia
collection PubMed
description BACKGROUND: No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for IDS and the prognosis-associated factors of International Federation of Gynecology and Obstetrics stage IIIc to IV HG-SOC patients. METHODS: A total of 160 IIIc to IV stage HG-SOC patients were retrospectively analyzed. Patients with large volume ascites underwent NAC and subsequent IDS from the Jiangsu Institute of Cancer Research between 1993 and 2013. The outcome of IDS-associated factors was explored by logistic regression. To predict IDS outcome, the potential values of serum CA-125 levels and CA-125 decreasing kinetics were determined by the receiver operating characteristic curve. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test. RESULTS: Optimal IDS was achieved in 80.6% of HG-SOC patients who underwent NAC. Multivariate analyses revealed that ascites regression (p = 0.01), serum CA-125 level (p = 0.02), and CA-125 decreasing kinetics (p = 0.01) were independent optimal IDS predictors. CA-125 decreasing kinetics, IDS outcome, and ascites volume were independently associated with overall survival (OS) (p = 0.04, p < 0.01, p = 0.03, respectively) and progression-free survival (PFS) (p < 0.01, p < 0.01, p = 0.02, respectively). Patients who exhibited disappearance of ascites (<500 ml) had longer PFS (19.7 months vs.14.9 months) and OS (32.1 months vs. 26.0 months) than patients who exhibited residual ascites (≥500 ml). Subsets with higher CA-125 decreasing kinetics (≥2.2) had longer PFS (21.4 months vs.13.1 months) and OS (29.6 months vs.26.8 months) than counterparts (kinetics < 2.2). CONCLUSIONS: Ascites regression and CA-125 decreasing kinetics were independently associated with surgical outcome and prognosis in advanced HG-SOC patients who underwent NAC.
format Online
Article
Text
id pubmed-5134071
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51340712016-12-15 Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer Xu, Xia Deng, Fei Lv, Mengmeng Ren, Binhui Guo, Wenwen Chen, Xiaoxiang J Ovarian Res Research BACKGROUND: No consensus exists on the outcome-related factors of interval debulking surgery (IDS) in patients with advanced high-grade serous ovarian cancer (HG-SOC) who underwent neoadjuvant chemotherapy (NAC). This study aimed to explore the optimal timing for IDS and the prognosis-associated factors of International Federation of Gynecology and Obstetrics stage IIIc to IV HG-SOC patients. METHODS: A total of 160 IIIc to IV stage HG-SOC patients were retrospectively analyzed. Patients with large volume ascites underwent NAC and subsequent IDS from the Jiangsu Institute of Cancer Research between 1993 and 2013. The outcome of IDS-associated factors was explored by logistic regression. To predict IDS outcome, the potential values of serum CA-125 levels and CA-125 decreasing kinetics were determined by the receiver operating characteristic curve. The associations between survival durations and covariates were assessed by Cox proportional hazards model and log-rank test. RESULTS: Optimal IDS was achieved in 80.6% of HG-SOC patients who underwent NAC. Multivariate analyses revealed that ascites regression (p = 0.01), serum CA-125 level (p = 0.02), and CA-125 decreasing kinetics (p = 0.01) were independent optimal IDS predictors. CA-125 decreasing kinetics, IDS outcome, and ascites volume were independently associated with overall survival (OS) (p = 0.04, p < 0.01, p = 0.03, respectively) and progression-free survival (PFS) (p < 0.01, p < 0.01, p = 0.02, respectively). Patients who exhibited disappearance of ascites (<500 ml) had longer PFS (19.7 months vs.14.9 months) and OS (32.1 months vs. 26.0 months) than patients who exhibited residual ascites (≥500 ml). Subsets with higher CA-125 decreasing kinetics (≥2.2) had longer PFS (21.4 months vs.13.1 months) and OS (29.6 months vs.26.8 months) than counterparts (kinetics < 2.2). CONCLUSIONS: Ascites regression and CA-125 decreasing kinetics were independently associated with surgical outcome and prognosis in advanced HG-SOC patients who underwent NAC. BioMed Central 2016-12-02 /pmc/articles/PMC5134071/ /pubmed/27912779 http://dx.doi.org/10.1186/s13048-016-0294-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Xu, Xia
Deng, Fei
Lv, Mengmeng
Ren, Binhui
Guo, Wenwen
Chen, Xiaoxiang
Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title_full Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title_fullStr Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title_full_unstemmed Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title_short Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
title_sort ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage iiic to iv high-grade serous ovarian cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134071/
https://www.ncbi.nlm.nih.gov/pubmed/27912779
http://dx.doi.org/10.1186/s13048-016-0294-z
work_keys_str_mv AT xuxia ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer
AT dengfei ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer
AT lvmengmeng ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer
AT renbinhui ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer
AT guowenwen ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer
AT chenxiaoxiang ascitesregressionfollowingneoadjuvantchemotherapyinpredictionoftreatmentoutcomeamongstageiiictoivhighgradeserousovariancancer